Tocilizumab in Active, Moderate-to-Severe, Glucocorticoid-Resistant Thyroid Eye Disease: An Open-Label Prospective Study in Two Independent Cohorts
Authors' conclusion
In this prospective, real-world study conducted in two independent cohorts of patients with GC-resistant, active, moderate-to-severe TED, TCZ was associated with clinically meaningful improvements in composite ophthalmic score response, CAS, proptosis, and quality of life, with a generally acceptable safety profile. These findings support TCZ as an effective and safe second-line therapeutic option for GC-resistant TED.
Study context
- Population
- Adults with active, moderate-to-severe, GC-resistant thyroid eye disease (TED); two tertiary TED referral centres, May 2022 to May 2025
- Participants
- 44 adults
- Exposure
- Warsaw vs Belgrade
- Warsawn = 32
- Belgraden = 12
- Outcome
- (1) Improvement in composite ophthalmic score and (2) improvement in disease-specific quality of life (GO-QoL)
- Follow-up
- 24 weeks
Methodological detailstwo tertiary referral centres, two independent cohorts
- Two tertiary referral centres
- Two independent cohorts
Main finding
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
CAS reduction by ≥2 points
Proptosis reduction ≥2 mm, diplopia improvement ≥1 Gorman grade, eyelid aperture decrease ≥2 mm
- Reported for each cohort; the abstract does not state which value belongs to which cohort
Median thyrotropin receptor antibody (TRAb) · baseline to follow-up
- Warsaw: median TRAb decreased from 7.0 to 2.1 IU/L
- Belgrade: median TRAb decreased from 4.7 to 2.0 IU/L
TED deterioration
- Patients with TED deterioration
- 0
Safety
TED deterioration
- Patients with TED deterioration
- 0
Adverse events
- Patients with adverse events
- 18/44 (40.9%)
- Adverse events
- 47 events
- Severe adverse events
- 1
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →